Last update 20 Mar 2025

Anselamimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Fibril-reactive monoclonal antibody 11-1F4
+ [2]
Target
Action
inhibitors
Mechanism
APP inhibitors(Beta amyloid A4 protein inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (European Union), Fast Track (United States)
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Immunoglobulin Light-Chain AmyloidosisPhase 3
France
03 Nov 2020
Immunoglobulin Light-Chain AmyloidosisPhase 3
Russia
03 Nov 2020
Immunoglobulin Light-Chain AmyloidosisPhase 3
France
03 Nov 2020
Immunoglobulin Light-Chain AmyloidosisPhase 3
Czechia
03 Nov 2020
Immunoglobulin Light-Chain AmyloidosisPhase 3
Spain
03 Nov 2020
Immunoglobulin Light-Chain AmyloidosisPhase 3
South Korea
03 Nov 2020
Immunoglobulin Light-Chain AmyloidosisPhase 3
Spain
03 Nov 2020
Immunoglobulin Light-Chain AmyloidosisPhase 3
Czechia
03 Nov 2020
Immunoglobulin Light-Chain AmyloidosisPhase 3
Brazil
03 Nov 2020
Immunoglobulin Light-Chain AmyloidosisPhase 3
United Kingdom
03 Nov 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
Immunoglobulin Light-Chain Amyloidosis
First line
N-terminal pro b-type natriuretic peptide (NT-proBNP) | involved/uninvolved free light chain difference (dFLC)
-
Anselamimab + CyBorD ± daratumumab
(lxbnhzbbmm) = wxgnapfsgk tovpfzafnq (qkvomhyehi, 2476 - 5758)
Positive
14 May 2024
Placebo + CyBorD ± daratumumab
(lxbnhzbbmm) = tvbrdfzgav tovpfzafnq (qkvomhyehi, 10254 - 22884)
Phase 1
22
(kfwlfwohnz) = No delayed adverse events occurred sjurgymlqz (ljwzwipxda )
Positive
31 May 2023
Phase 2
25
(dufcpeamls) = tlfyiyresj heskmkqbpl (ygfqwavmyk )
Positive
05 Nov 2021
Phase 2
13
CAEL-101+CyBorD
eczilodmth(snobgoobzr) = yvlhxpjpjf warshrggrk (xebimfzusx )
-
09 Jun 2021
Phase 2
13
(uegiqldokn) = none aksqqvjoml (nnzstomqfp )
Positive
05 Nov 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free